4 -12 (50) 2022 — Aripova N.A., Djurayeva E.R. — VALUE OF INTERLEUKIN — 4 IN SYSTEMIC SCLERODERMA

VALUE OF INTERLEUKIN – 4 IN SYSTEMIC SCLERODERMA

Aripova N.A. Tashkent Medical Academy

Djurayeva E.R. Tashkent Medical Academy

Resume

Target. To study the relationship between the serum level of interleukin-4 (IL-4) and visceral pathology, the nature of the course and clinical forms of systemic scleroderma (SS). Materials and methods. IL-4 was determined in the sera of 60 patients with SS by an indirect enzyme-linked immunosorbent assay. Results. The level of IL-4 in the range of 10-1000pg/ml was detected in 18 out of 60 patients with SS (30%). Distinctive features of this group of patients were a shorter duration of the disease, progression of skin fibrosis and visceral pathology by the time of the examination, and a tendency towards a higher incidence of pulmonary fibrosis. Significant differences in the damage to other internal organs, as well as the dependence of the content of IL-4 on the clinical forms and course of the disease, were not revealed. In patients with an increase in IL-4 in the blood, higher levels of circulating immune complexes (CIC), γ-globulins were noted, while the content of acute phase reactants was lower than in the rest of the group. Conclusion. The established relationship between the serum level of IL-4 and the activity of the fibrous process in SS requires confirmation in prospective studies.

Keywords: interleukin-4. T lymphocytes, fibrosis, activity, systemic scleroderma.

First page

18

Last page

24

For citation: Aripova N.A., Djurayeva E.R. – VALUE OF INTERLEUKIN – 4 IN SYSTEMIC SCLERODERMA //New Day in Medicine 12(50)2022 18-24 https://clck.ru/3354Ki

LIST OF REFERENCES:

  1. Ананьева  Л.П.  Александрова  Е.Н.  Аутоантитела  при  системной склеродермии:  спектр,  клинические  ассоциации  и  прогностическое значение  //Научно-практическая  ревматология.  2018.  Vol.  54,  №  1.  P. 86-99.
  2. Adigun R., Goyal A., Bansal P., Hariz A. Systemic Sclerosis. 9 May 2021. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2021.].
  3. Agarwal S.K., Reveille J.D. The genetics of scleroderma (systemic sclerosis). //Curr. Opin. Rheumatol. 2017;22(2):133–8.].
  4. Al-Dhaher F.F, Pope J.E, Ouimet J.M. Determinants of morbidity and mortality of systemic sclerosis in Canada. //Semin Arthritis Rheum 2018;39(4):269-77. ].
  5. Arcangeletti M.C., D’Accolti M., Maccari C., Soffritti I., De Conto F., Chezzi C., Calderaro A., Ferri C., Caselli E. Impact of Human Cytomegalovirus and Human Herpesvirus 6 Infection on the Expression of Factors Associated with Cell Fibrosis and Apoptosis: Clues for Implication in Systemic Sclerosis Development. Int. J. Mol. Sci. 2020, 21, 6397.
  6. Atamas  S.P.,  Yurovsky  V.V.,  Wise  R.  Production  of  type  2 cytokines  by  CD8+  lung  cells  is  associated  with  greater  decline in  pulmonary  function  in  patients  with  systemic  sclerosis.  //Arthr. Rheum.,  2017,  42(6),  1168-78.]
  7. Bairkdar M., Rossides M., Westerlind H., Hesselstrand R., Arkema E.V., Holmqvist M. Incidence and prevalence of systemic sclerosis globally: A comprehensive systematic review and meta-analysis. //Rheumatology 2021, 60, 3121–3133.
  8. Bolster M.B., Ludwicka A., Sutherland S.E. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis //Arthr.Rheum. — 2017. – V.40. – N.4. – P.743-751.
  9. Dees C., Pötter S., Zhang Y., Bergmann C., Zhou X., Luber M., Wohlfahrt T., Karouzakis E., Ramming A., Gelse K., et al.TGF-β-induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis. //J. Clin. Investig. 2020, 130,2347–2363.
  10. Ferri  C.  et  al.  Systemic  sclerosis:  Demographic,  clinical,  and  serologic features  and  survival  in  1,012  Italian  patients  //Medicine  (Baltimore). Medicine (Baltimore), 2020. Vol. 81, № 2. P. 139–153.
  11. Gourh P. et al. Association of the PTPN22 R620W polymorphism with anti-topoisomerase  I-  and  anticentromere  antibody-positive  systemic  sclerosis  //Arthritis Rheum. Arthritis Rheum, 2016. Vol. 54, № 12. P. 3945–3953.
  12. Hu  P.Q.  et  al.  Correlation  of  serum  anti-DNA  topoisomerase  I  antibody levels  with  disease  severity  and  activity  in  systemic  sclerosis  //Arthritis Rheum. Arthritis Rheum, 2018. Vol. 48, № 5. P. 1363–1373.].
  13. Hughes M., Pauling J., Armstrong-James L., Denton C.P., Galdas P.M., Flurey C. Gender-related differences in systemic sclerosis. //Autoimmun. Rev. 2020, 19, 1024-94.
  14. Kahaleh MB. Lymphocyte interactions with the vascular endothelium in systemic sclerosis //Clinics in Dermatol. — 2019. — V.12. — P.361-367. ].
  15. Karrer S., Bosserhoff A.K., Weiderer P., Landthaler M., Szeimies R.M. Keratinocyte-derived cytokines after photodynamic therapy and their paracrine induction of matrix metalloproteinases in fibroblasts. //Br J Dermatol 2018; 151: 4: 776—783.]
  16. Kuroda  K.,  Shinkai  H.  Downregulated  of decorin  expression in  dermal  fibroblasts  by  interleukin-4.  //Arch.  Dermatol.  Res.,1997,  289,  476-480.
  17. Lee  K.S.,  Ro  Y.J.,  Ryoo  Y.W.,  Kwon  H.S.  Regulation  of interleukin-4  on  collagen  gene  expression  in  systemic  sclerosis  fibroblast  culture.  //J.  Dermatol.  Sci.,  2017,  12(2),  110-117.].
  18. Ludwig R.J., Werner R.J., Winker W., Boehncke W.H., Wolter M., Kaufmann R. Chronic venous insufficiency — a potential trigger for localized scleroderma. //J Eur Acad Dermatol Venereol 2019; 20: 1: 96—99.]
  19. Needleman B.W., Wigley F.M., Stair R.W. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma //Arthr.Rheum. — 2018. — V.35. — N.I.-P.67-72.
  20. Ong C.,  Wong  C.,  Roberts  C.R.,  Teh  H.S.  Anti-IL-4  treatment prevents  dermal  collagen  deposition  in  the  tight-skin  mouse model  of scleroderma.  //Eur.  J.  Im m unol.,  2018,  28(9),  2619 – 2629.].

file

download